Blumenthal H J, Weisz M A, Burk S
Department of Internal Medicine, University of Oklahoma College of Medicine-Tulsa 74129-1077, USA.
J Okla State Med Assoc. 1996 Jan;89(1):7-10.
Forty consecutive headache patients self-administered sumatriptan for migraine, diagnosed by the criteria of the International Headache Society (IHS). Eighty percent reported excellent response. Thirty-three percent had recurrence of headache within four to twelve hours, while 67% had no recurrence. Fifty-five percent of the patients reported mild side effects, but only 8% stopped therapy because of adverse reactions. No serious cardiovascular events occurred. Recommendations for safe use of sumatriptan are suggested.
连续40例头痛患者按照国际头痛协会（IHS）的标准诊断为偏头痛后自行服用舒马曲坦。80%的患者报告有良好反应。33%的患者在4至12小时内头痛复发，而67%的患者未复发。55%的患者报告有轻微副作用，但只有8%的患者因不良反应而停止治疗。未发生严重心血管事件。文中给出了舒马曲坦安全使用的建议。
